GSK said it plans to sell its $1 billion stake in consumer health spinoff Haleon. The 240 million shares account for 2.5% of Haleon. (Bloomberg)
The World Health Organization said Mpox was no longer a global health emergency. This decision ends a nearly year-long alert for the viral disease that led to confirmed cases in more than 100 countries. (CNN)
The Food and Drug Administration rejected a biologics license application for a specific bladder cancer drug from Patrick Soon-Shiong’s ImmunityBio. The agency cited deficiencies related to an inspection of a third-party contract manufacturer, ImmunityBio said in an SEC filing, noting the “satisfactory resolution of the observations” is needed before a BLA approval. (Endpoints News)
A pancreatic cancer vaccine provoked an immune response in half of the patients treated in a small trial, a finding that experts described as very promising. The patients that were treated also showed no relapse of their cancer during the course of the study. (The New York Times)
OptimizeRx came out with a quarterly loss of $0.09 per share versus analyst estimates of a loss of $0.08. This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this company would post earnings of $0.24 per share when it actually produced earnings of $0.25, delivering a surprise of 4.17%. (Yahoo! Finance)
